Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

Important Disclosures:

1. Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Key Investor Takeaways

• Sernova and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics Inc., with each company's shareholders expecting to own approximately 50% on a non-diluted basis.
• BetaNova would combine Seraxis' stem cell-derived islet programs and cGMP manufacturing with Sernova's Cell Pouch Bio-hybrid Organ.
• The companies plan to enroll patients in Q4 2026 for a Phase 1/2 trial of SR-02, with first dosing in Q1 2027 and initial clinical data anticipated in H1 2027.
• Other targets include Nasdaq listing readiness in Q1 2027 and an IND submission for the gene-edited SR-03 program in H2 2027.
• The September 8 merger release targeted a November 2026 closing, subject to shareholder, court, and Toronto Stock Exchange approval.
• A US$11.2 million convertible note financing, above the US$10 million target, closed in connection with the merger, with insiders of both companies taking part.
• H.C. Wainwright & Co. reaffirmed a Buy rating and CA$1 price target on September 14. Research Capital Corp. maintained a Speculative Buy and temporarily suspended its target pending shareholder approval of the merger.
• About 9.5 million people worldwide live with type 1 diabetes, including 1.5 million in the United States, according to Breakthrough T1D.

Merger Moves Ahead With 2027 Trial in Sight

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward completion of their proposed merger to form BetaNova Biotherapeutics Inc., with plans to begin dosing patients with a type 1 diabetes cell therapy in Q1 2027, according to an October 5 release.

The combined company would pair Seraxis' stem cell-derived pancreatic islet programs and current Good Manufacturing Practice (cGMP) manufacturing capabilities with Sernova's Cell Pouch Bio-hybrid Organ. On completion, each company's shareholders are expected to own approximately 50% of BetaNova on a non-diluted basis. The companies said the merger remains subject to required approvals and customary closing conditions.

The release set out the milestones the companies are working toward. They include cGMP manufacturing of SR-02, Seraxis' allogeneic stem cell-derived pancreatic islet cells, and enrollment of patients in Q4 2026 for a Phase 1/2 clinical trial. First patient dosing is planned for Q1 2027 under an investigational new drug application (IND) cleared by the U.S. Food and Drug Administration, with initial clinical data anticipated in H1 2027. The companies are also targeting Nasdaq listing readiness in Q1 2027, subject to listing requirements and approvals, and an IND submission in H2 2027 for SR-03, a next-generation gene-edited islet cell program targeting immune evasion.

Sernova President and Chief Executive Officer Jonathan Rigby said the companies believe "BetaNova is positioned to successfully compete with other companies in the T1D cell therapy space by entering the clinic in the near term."

"Our focus is on execution, while deploying capital efficiently," Rigby said in the release.

"As we work toward completion of the Merger, our teams are aligned around a shared mission, a clear development strategy, and a defined set of milestones for 2026 and 2027," said Will Rust, president and chief executive officer of Seraxis.

Inside the BetaNova Combination

Sernova and Seraxis signed a definitive merger agreement on September 7, 2026. According to the September 8 release announcing the deal, the merger would be carried out through a plan of arrangement, and BetaNova would be a U.S.-domiciled company headquartered in Germantown, Maryland. Rigby is to serve as CEO, Rust as president and chief scientific officer, and James Parsons as chief financial officer.

That release targeted a closing in November 2026, subject to approval by Sernova and Seraxis shareholders, the court, and the Toronto Stock Exchange. Noble Capital Markets Inc. is acting as the exclusive financial adviser to Sernova on the merger.

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova.

Sernova describes itself as a clinical-stage company developing a regenerative medicine approach to type 1 diabetes that combines its Cell Pouch Bio-hybrid Organ with therapeutic cells to create a functional surrogate endocrine organ. In the September release, the company said patient treatment and follow-up in its Phase 1/2 study of the Cell Pouch with human donor islets was complete and that all primary and secondary endpoints were met.

Seraxis develops stem cell-derived pancreatic islets under cGMP manufacturing processes. Its lead product, SR-02, is paired with an immune tolerizing strategy, and its follow-on, SR-03, adds gene edits intended to increase compatibility with the host, according to the October 5 release. The company's stated aim is to show the safety and potency of its islets in patients without immune suppression therapy.

Management of Both Companies Buys In

The companies said the milestones are to be supported by a US$11.2 million non-brokered financing that closed in connection with the merger, above the US$10 million they had targeted. It was made into Seraxis and consists of convertible notes and Seraxis common stock purchase warrants. The notes are expected to convert automatically into BetaNova common stock when the merger is completed. The release did not give the conversion price, interest rate, or warrant terms.

Insiders of both companies took part. The release named Dr. Steven Sangha / Arlo Investments, along with Sernova's Rigby, Parsons, Chief Communications Officer Marylyn Rigby, and Vice President of Investor Relations David Burke. From Seraxis, Rust, and Chief Operating Officer Carole Welsch participated, as did existing shareholders and new investors.

"Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial," Rust said.

Type 1 Diabetes: A Growing Patient Base and Treatment Market

About 9.5 million people worldwide are living with type 1 diabetes, including 1.5 million in the United States, according to Breakthrough T1D, the research and advocacy organization formerly known as JDRF, in figures updated December 2, 2025. Of the U.S. total, about 199,000 are under the age of 20, and most Americans with the condition are between 45 and 65.

The organization describes type 1 diabetes as "one of the fastest-growing, noncommunicable, chronic health conditions on the planet" and said its prevalence is increasing across all populations.

Research Capital Corp. analyst Andre Uddin separately maintained a Speculative Buy rating.

The market for treating the disease is expanding with that population. In a report published in September 2026, The Business Research Company estimated the global type 1 diabetes market at US$13.5 billion in 2025 and US$15.27 billion in 2026, and forecast it would reach US$25.73 billion by 2030, a compound annual growth rate of 13.9%.

The firm cited growing adoption of closed-loop insulin delivery systems and rising investment in immunotherapy research as drivers. Its report covers insulin products and devices such as pumps, pens, and glucose meters.

Cell-based approaches, such as the one BetaNova is pursuing, are tracked separately. A February 2026 report from The Business Research Company, distributed by Research and Markets, put the diabetes stem cell therapy market at US$3.01 billion in 2025 and US$3.38 billion in 2026, with a forecast of US$5.29 billion by 2030, or annual growth of 11.9%. It pointed to rising diabetes prevalence, early-stage success in stem cell research, and increasing clinical trial activity, and it named both Sernova and Seraxis among the companies in the field.

Analysts See a Fit in the BetaNova Combination

H.C. Wainwright & Co. analyst Joseph Pantginis reaffirmed a Buy rating and CA$1 price target on Sernova in a September 14 research note following the company's webinar on the proposed merger. The shares traded at CA$0.10 on September 11, according to the report.

Pantginis said the firm considers the webinar "supportive of the combined platform, with encouraging SR-02 preclinical data and prior Cell Pouch clinical experience providing a solid foundation for development." He noted that the Phase 1/2 trial will initially test SR-02 on its own to assess safety and dose response before pairing the cells with the Cell Pouch, which he considered a sensible progression. He identified the SR-02 results expected in the first half of 2027 as "the key near-term clinical catalyst."

The analyst also pointed to gaps in the evidence available to date. He noted that previous Cell Pouch clinical results involved islets from cadaveric donors rather than SR-02, while the prospect of reducing immunosuppression is "still something that will need to be demonstrated clinically."

Pantginis based his CA$1 target on a clinical net present value model that gives both SR-02 and SR-03 a 10% probability of success, which he suggested may prove conservative. He sees "blockbuster potential" for both programs based on anticipated launches in 2032 and 2033. Following completion of the merger, the firm expects a reverse split, financing during the first half of 2027, alongside a U.S. listing and a transition to U.S. dollar reporting, none of which is reflected in its model. Key risks include unsuccessful or inconclusive clinical trials, insufficient access to capital and dilution from future financings.

Research Capital Corp. analyst Andre Uddin separately maintained a Speculative Buy rating on September 14, when the shares traded at CA$0.12. He temporarily suspended the firm's target price and valuation "until we see that the merger is approved by shareholders."

After reviewing Seraxis' pipeline, Uddin wrote, "we believe SVA has found the right merger partner." He said SR-02 and SR-03 complement the Cell Pouch.

He cited Seraxis' established cell bank and internal cGMP manufacturing capabilities, the fact that its cells do not require a final sorting step, and the selection of the original cell donor for transplant compatibility.

Uddin recommended that investors pay close attention to the immunosuppression protocol selected for the upcoming trial because the optimal balance for patients remains unresolved. He wrote that Sernova shareholders "effectively receive exposure to 50% of a potentially much more valuable biotech platform." His risk factors include completing the merger, raising substantially more capital, and limited liquidity in the shares.

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 10.51%, Chief Financial Officer James Parsons with 0.16%, CEO Rigby with 0.06%, and CATAM Asset Management AG with 0.04%.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$39.73 million. Its 52-week range is CA$0.09−CA$0.20 per share.

Common Questions from Investors

What is BetaNova Biotherapeutics? BetaNova is the proposed combined company of Sernova and Seraxis. It would be a U.S.-domiciled company based in Germantown, Maryland, with Jonathan Rigby as CEO, James Parsons as chief financial officer, and Will Rust as president and chief scientific officer.

When is the merger expected to close? The September 8 release targeted closing in November 2026. Completion remains subject to approval by both companies' shareholders, the court, and the Toronto Stock Exchange, along with customary closing conditions.

What are the next clinical milestones? The companies plan to enroll patients in Q4 2026 for a Phase 1/2 trial of SR-02, dose the first patient in Q1 2027, and report initial clinical data in H1 2027. An IND submission for SR-03 is targeted for H2 2027.

Will the first trial combine SR-02 with the Cell Pouch? According to H.C. Wainwright analyst Joseph Pantginis' account of the company's webinar, the Phase 1/2 trial will initially test SR-02 on its own to assess safety and dose response before the cells are paired with the Cell Pouch Bio-hybrid Organ.

Will BetaNova list on Nasdaq? The companies are targeting Nasdaq listing readiness in Q1 2027, subject to listing requirements and approvals.

How is the plan being funded? A US$11.2 million non-brokered financing of convertible notes and warrants closed in connection with the merger. Insiders of both companies participated, and the notes are expected to convert into BetaNova common stock when the merger is completed.

What are analysts saying? H.C. Wainwright reaffirmed a Buy rating and CA$1 target on September 14 and called the SR-02 data expected in the first half of 2027 the key near-term catalyst.

Research Capital maintained a Speculative Buy and said Sernova "has found the right merger partner."